Panel-derived tumor mutational burden (TMB) is associated with the response to the immune checkpoint inhibitors (ICIs) in urothelial cancers

被引：0
|
作者：
Hsieh, Yi-Lin [1 ]
Yu, Pei-Ning [1 ]
Jan, Yi-Hua [1 ]
Lai, Meng-Shao [1 ]
Wang, Woei-Fuh [1 ]
Zhuo, De-Wei [1 ]
Chen, Shu-Jen [1 ]
Cheng, Jen-Hao [1 ]
Tan, Kien Thiam [1 ]
Su, Yu-Li [2 ]
机构：
[1] ACT Genom, Taipei, Taiwan
[2] Chang Gung Mem Hosp, Kaohsiung, Taiwan
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-3177
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3177
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Panel-derived tumor mutational burden (TMB) correlates with immune checkpoint inhibitors (ICIs) response in gastrointestinal cancers
    Chen, San-chi
    Tan, Kien-Thiam
    Chen, Ming-Huang
    Hung, Yi-Ping
    Hsieh, Yi-Lin
    Jan, Yi-Hua
    Chao, Yee
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [2] Panel-derived TMB and immune-related GEP are associated with the response to immune checkpoint inhibitors (ICIs) in urothelial cancers.
    Tan, Kien Thiam
    Chen, Shu-Jen
    Hsieh, Yi-Lin
    Su, Yu-Li
    Jan, Yi-hua
    Cheng, Jen Hao
    Hsu, An
    Huang, Wan-Ting
    Zhuo, De-Wei
    Wang, Woei-Fuh
    Wei, Datsen George
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] Association of biomarkers and response to immune checkpoint inhibitors (ICIs) in patients with metastatic urothelial carcinoma (mUC) with high and low tumor mutation burden (TMB).
    Jindal, Tanya
    Zhu, Xiaolin
    Zhang, Li
    Reyes, Kevin R.
    Deshmukh, Prianka
    de Kouchkovsky, Ivan
    Kumar, Vipul
    Maldonado, Edward
    Shipp, Chase
    Kwon, Daniel H.
    Borno, Hala
    Bose, Rohit
    Desai, Arpita
    Aggarwal, Rahul Raj
    Porten, Sima P.
    Small, Eric Jay
    Fong, Lawrence
    Chou, Jonathan
    Friedlander, Terence W.
    Koshkin, Vadim S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [4] Tumor mutational burden (TMB) and response rates to immune checkpoint inhibitors (ICIs) targeting PD-1, CTLA-4, and combination.
    Osipov, Arsen
    Popovic, Aleksandra
    Hopkins, Alexander
    Frampton, Garrett M.
    Albacker, Lee A.
    Azad, Nilofer Saba
    Laheru, Daniel A.
    Zheng, Lei
    Jaffee, Elizabeth M.
    Yarchoan, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Tissue tumor mutational burden (TMB) as a biomarker of efficacy with immune checkpoint inhibitors (ICI) in metastatic gastrointestinal (mGI) cancers.
    Lentz, Robert William
    Friedrich, Tyler
    Hu, Junxiao
    Leal, Alexis Diane
    Kim, Sunnie S.
    Davis, S. Lindsey
    Purcell, Tom
    Messersmith, Wells A.
    Lieu, Christopher Hanyoung
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] The Now and Beyond of Tumor Mutational Burden as a Predictor of Response to Immune Checkpoint Inhibitors
    Nandakumar, Vijayalakshmi
    Mills, John R.
    CLINICAL CHEMISTRY, 2019, 65 (02) : 357 - 357
  • [7] Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC).
    Labriola, Matthew
    Zhu, Jason
    Gupta, Rajan
    McCall, Shannon
    Jackson, Jennifer
    White, James R.
    Weingartner, Elizabeth
    Kong, Eric
    Simone, Peter
    Papp, Eniko
    Gerding, Kelly
    Simmons, John
    George, Daniel J.
    Zhang, Tian
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [8] Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC).
    Labriola, Matthew
    Zhu, Jason
    Gupta, Rajan
    McCall, Shannon
    Jackson, Jennifer
    White, James R.
    Weingartner, Elizabeth
    Kong, Eric
    Simone, Peter
    Papp, Eniko
    Gerding, Kelly
    Simmons, John
    George, Daniel J.
    Zhang, Tian
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Hot or Not: Tumor Mutational Burden (TMB) as a Biomarker of Immunotherapy Response in Genitourinary Cancers
    Halbert, Brian
    Einstein, David J.
    UROLOGY, 2021, 147 : 119 - 126
  • [10] Persistent Tumor Mutational Burden (pTMB) May Predict Response to Immune Checkpoint Inhibitors
    Smith, Katherine E. R.
    Markovic, Svetomir N.
    CLINICAL CHEMISTRY, 2024, 70 (01) : 25 - 26
12345